CJC-1295 With DAC vs CJC-1295 Without DAC: Research Comparison
CJC-1295 is a synthetic analogue of growth hormone–releasing hormone (GHRH) commonly used in laboratory and analytical research exploring growth hormone (GH) and insulin-like growth factor-1 (IGF-1) signalling pathways. Two primary variants are widely available: CJC-1295 with DAC and CJC-1295 without DAC (often referred to as Mod-GRF 1-29).
While both peptides act on the same receptor pathway, the presence or absence of the Drug Affinity Complex (DAC) results in distinct pharmacokinetic and signalling profiles. Understanding these differences is essential when selecting a compound for a specific research objective.
What Is CJC-1295?
CJC-1295 is designed to activate the growth hormone–releasing hormone receptor (GHRHR), triggering intracellular signalling cascades that stimulate GH secretion. Structural modifications improve stability compared with native GHRH while maintaining receptor specificity.
More background information on CJC-1295 can be found here: https://en.wikipedia.org/wiki/CJC-1295
CJC-1295 With DAC: Long-Acting GHRH Analogue
CJC-1295 with DAC includes a Drug Affinity Complex that enables reversible binding to serum albumin. This binding dramatically extends the peptide’s functional lifespan by reducing enzymatic degradation and clearance.
Key Research Characteristics
- Extended persistence due to albumin binding
- Sustained activation of GHRH receptors
- Prolonged GH and IGF-1 signalling in experimental models
In controlled trials, this extended activity has been shown to maintain elevated GH signalling for prolonged observation periods, making it useful for long-duration or longitudinal research designs.
Further reading: Prolonged stimulation of GH and IGF-1 secretion by CJC-1295
Typical Research Applications
- Chronic GH axis modulation studies
- Long-term endocrine signalling analysis
- Experiments requiring stable baseline elevation
View product: CJC-1295 With DAC
CJC-1295 Without DAC (Mod-GRF 1-29)
CJC-1295 without DAC, also known as Mod-GRF 1-29, lacks albumin-binding capability. As a result, it exhibits a much shorter functional lifespan and more transient receptor activation.
Key Research Characteristics
- Rapid degradation and clearance
- Pulsatile GH signalling patterns
- High temporal control for experimental timing
Trials have demonstrated that this variant produces GH release patterns that more closely resemble endogenous pulsatility, making it valuable for mechanistic and physiological signalling research.
Typical Research Applications
- Short-term receptor dynamics studies
- GH pulse timing experiments
- Acute signalling pathway research
View product: CJC-1295 Without DAC
CJC-1295 With DAC vs Without DAC: Comparison
| Feature | With DAC | Without DAC |
|---|---|---|
| Functional lifespan | Extended | Short |
| GH signalling pattern | Sustained | Pulsatile |
| Temporal control | Lower | High |
| Primary research use | Chronic signalling models | Acute or mechanistic studies |
Research Context and Mechanistic Insight
Both variants activate the GHRH receptor and downstream signalling pathways, including cAMP-mediated mechanisms involved in GH secretion. Differences in pharmacokinetics allow researchers to select the most appropriate tool based on study duration, signal timing, and analytical endpoints.
Additional reading on GHRH receptor signalling: Growth hormone-releasing hormone receptor mechanisms
Research-Only Disclaimer
All peptides sold by New Wave Peptides are supplied strictly for laboratory research and educational purposes only. They are not approved for human or veterinary use and are not intended for consumption. Information provided here relates solely to experimental and analytical research contexts.
